China's CStone ramps up yet another PD-1 clinical trial for solid tumors; Takeda faces profit decline on loss of Velcade exclusivity
→ Just how many PD-1/L1s does the world need to treat cancer?
With Regeneron and Sanofi within quick reach of their PDUFA date for number 6, and several under regulatory review in China, we may find that out fairly quickly. But as we’ve seen from research at Cancer Research Institute, there are some 164 projects around the world. And a high profile China startup called CStone just launched another clinical program for their PD-1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
